Inclusion Criteria:

- Any autologous or syngeneic patient who underwent high dose melphalan (>= 140 mg/m^2)
therapy/peripheral blood stem cell (PBSC) or bone marrow (BM) rescue for any stage of
multiple myeloma and did not participate in another clinical transplant trial which
is also evaluating long-term disease free survival or survival

- Platelet count (transfusion independent) > 50,000 cells/mm^3 and absolute granulocyte
count > 1500 cells/mm^3 for 5 calendar days after recovery from high dose therapy

- Patients should be between 30 days to 120 days after transplant

- Willingness and ability to comply with Food and Drug Administration (FDA)-mandated
REV ASSIST Program, Celgene System for Lenalidomide Education and Prescribing Safety

- Signing a written informed consent form

Exclusion Criteria:

- Karnofsky score less than 70

- A left ventricular ejection fraction less than 45% immediately pre transplant;
patients with congestive heart disease with transplant, history of MI, or history of
coronary artery disease

- Total bilirubin greater than 2 mg/ml (unless history of Gilbert's disease), SGOT or
SGPT > 2.5 x upper limit of normal

- Calculated by Cockcroft-Gault formula or measured serum creatinine clearance < 25
ml/minute

- Pregnant and/or lactating females

- Patients who cannot give informed consent

- Patients with untreated systemic infection

- Patients with history prior to transplant of treatment with combination therapy
Lenalidomide/Biaxin and Steroid without response

- Patients allergic to Lenalidomide, Biaxin or Dexamethasone

- Referring physician not registered with REV ASSIST program or unwilling to oversee
the care of the patients on study and comply with the FDA-mandated REV ASSIST Program

- Patients unwilling to practice adequate forms of contraception if clinically
indicated until 30 days after stopping therapy; male patients on study need to be
consulted to use latex condoms (even if they have had a vasectomy) every time they
have sex with a woman who is able to have children while they are being treated and
for 30 days after stopping drugs

- Patients with >= grade 3 peripheral neuropathy

- Prior history of uncontrollable side effects to Dexamethasone therapy

- A prior history of human immunodeficiency virus (HIV) positivity with pre-transplant
evaluation